February 1961 in “The Lancet” Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly”
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
38 citations
,
November 2005 in “Epilepsia” Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
June 2026 in “British Journal of Dermatology” Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.